36Kr's 15min chart shows bullish signs with KDJ Golden Cross and Marubozu.
PorAinvest
miércoles, 8 de octubre de 2025, 11:04 am ET2 min de lectura
AMGN--
Institutional investors have also shown increased confidence in Amgen. Dohj LLC, for instance, increased its stake in Amgen by 60% during the 2nd quarter, bringing its total holdings to 5,963 shares valued at approximately $1.66 million [1]. This is part of a broader trend where a significant number of institutional investors have enhanced their positions in Amgen, with notable increases including CBIZ Investment Advisory Services LLC raising its stake by 1,214.3% and Nova Wealth Management Inc. by 12,200% in the past quarter [1].
Additionally, insiders have also placed their bets on Amgen. SVP Nancy A. Grygiel sold 1,267 shares of the company's stock in a transaction that occurred on Wednesday, August 20th, but the sale represented a 14.95% decrease in their ownership of the stock [1]. Despite this, the senior vice president still owns 7,209 shares of the company's stock, valued at $2,141,000.91 [1].
Wall Street analysts have also been optimistic about Amgen's prospects. Several analysts have raised their ratings and target prices for the stock. For example, Piper Sandler raised their price target on shares of Amgen from $328.00 to $342.00 and gave the company an "overweight" rating [1]. Citigroup also upped their target price on shares of Amgen from $310.00 to $315.00 and gave the stock a "neutral" rating [1].
Amgen's financial performance has also been strong. The company reported $6.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.28 by $0.74 [1]. The company had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion [1]. Amgen had a net margin of 18.96% and a return on equity of 174.71% [1]. The firm's revenue was up 9.4% compared to the same quarter last year [1].
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were issued a dividend of $2.38 per share [1]. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2% [1].
In conclusion, Amgen Inc. (AMGN) has shown a significant shift in its stock price momentum, with bullish indicators such as the KDJ Golden Cross and Bullish Marubozu. Institutional investors and insiders have also shown increased confidence in the company, and Wall Street analysts have been optimistic about Amgen's prospects. The company's financial performance has also been strong, with a significant increase in earnings and revenue compared to the same quarter last year.
KRKR--
As per 36Kr's 15-minute chart, a bullish indicator has been triggered, namely the KDJ Golden Cross, coupled with a Bullish Marubozu at 10/08/2025 11:00. This suggests that the momentum of the stock price is shifting towards the upside, potentially leading to further increases. The control of the market is now in the hands of buyers, and it is likely that bullish momentum will continue.
Amgen Inc. (AMGN) has shown a significant shift in its stock price momentum, according to the latest technical analysis. As per 36Kr's 15-minute chart, a bullish indicator has been triggered, namely the KDJ Golden Cross, coupled with a Bullish Marubozu at 10/08/2025 11:00. This suggests that the momentum of the stock price is shifting towards the upside, potentially leading to further increases. The control of the market is now in the hands of buyers, and it is likely that bullish momentum will continue [1].Institutional investors have also shown increased confidence in Amgen. Dohj LLC, for instance, increased its stake in Amgen by 60% during the 2nd quarter, bringing its total holdings to 5,963 shares valued at approximately $1.66 million [1]. This is part of a broader trend where a significant number of institutional investors have enhanced their positions in Amgen, with notable increases including CBIZ Investment Advisory Services LLC raising its stake by 1,214.3% and Nova Wealth Management Inc. by 12,200% in the past quarter [1].
Additionally, insiders have also placed their bets on Amgen. SVP Nancy A. Grygiel sold 1,267 shares of the company's stock in a transaction that occurred on Wednesday, August 20th, but the sale represented a 14.95% decrease in their ownership of the stock [1]. Despite this, the senior vice president still owns 7,209 shares of the company's stock, valued at $2,141,000.91 [1].
Wall Street analysts have also been optimistic about Amgen's prospects. Several analysts have raised their ratings and target prices for the stock. For example, Piper Sandler raised their price target on shares of Amgen from $328.00 to $342.00 and gave the company an "overweight" rating [1]. Citigroup also upped their target price on shares of Amgen from $310.00 to $315.00 and gave the stock a "neutral" rating [1].
Amgen's financial performance has also been strong. The company reported $6.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.28 by $0.74 [1]. The company had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion [1]. Amgen had a net margin of 18.96% and a return on equity of 174.71% [1]. The firm's revenue was up 9.4% compared to the same quarter last year [1].
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were issued a dividend of $2.38 per share [1]. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2% [1].
In conclusion, Amgen Inc. (AMGN) has shown a significant shift in its stock price momentum, with bullish indicators such as the KDJ Golden Cross and Bullish Marubozu. Institutional investors and insiders have also shown increased confidence in the company, and Wall Street analysts have been optimistic about Amgen's prospects. The company's financial performance has also been strong, with a significant increase in earnings and revenue compared to the same quarter last year.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios